 |
13 Companies | 15 Products |
|
|
15 Products | |
46 Diseases | |
8 Trials |  |
488 News |  |
| «12...345678910111213...1617» |
- azacitidine / Generic mfg.
[VIRTUAL] Myeloid sarcoma: a rare cutaneous presentation of myelodysplastic syndrome transformation () - Sep 9, 2020 - Abstract #BAD2020BAD_38;
Hydroxycarbamide was started...Although there is no consensus on treatment, options include systemic chemotherapy, bone marrow transplantation and local radiotherapy. Prognosis is poor, with patients rarely surviving more than 1 year after diagnosis.
- || Clinical, Journal: Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. (Pubmed Central) - Sep 8, 2020
While the promise of a more targeted chemotherapy with less toxicity has not yet been realized with ADCs, improvements in technology combined with a wealth of clinical data are helping to shape the future development of ADCs. In this review we discuss the clinical and translational strategies associated with improving the therapeutic index for ADCs.
- [VIRTUAL] An advanced in silico drug discovery platform, 4HF Data Miner for identifying novel targets for tumors and tumor-stroma () - Sep 7, 2020 - Abstract #AACRNCIEORTC2020AACR_NCI_EORTC_152;
In parallel, by the data-driven screening approaches, we have developed an innovative methodology to prioritize novel targets that paves the way for the development of new ADCs with an enhanced therapeutic index. At this juncture, it is noteworthy to mention that many novel targets have been identified by the 4HF cancer Data Miner across a wide range of tumor types including several solid cancers for the development of novel ADCs.
- [VIRTUAL] An advanced in silico drug discovery platform, 4HF Data Miner for identifying novel targets for tumors and tumor-stroma () - Sep 7, 2020 - Abstract #AACRNCIEORTC2020AACR_NCI_EORTC_151;
In parallel, by the data-driven screening approaches, we have developed an innovative methodology to prioritize novel targets that paves the way for the development of new ADCs with an enhanced therapeutic index. At this juncture, it is noteworthy to mention that many novel targets have been identified by the 4HF cancer Data Miner across a wide range of tumor types including several solid cancers for the development of novel ADCs.
- || Clinical, Journal: A Case of t(1;6)(p12;p11.1), Deletion 5q, and Ring 11 in a Patient with Myelodysplastic Syndrome with Excess Blasts Type 1. (Pubmed Central) - Sep 6, 2020
Chromosome analysis of the bone marrow revealed an abnormal karyotype with a t(1;6)(p12;p11.1) as well as deletion 5q and a ring 11 in 12 of the 20 metaphase cells examined. The t(1;6)(p12;p11.1) has not been reported in association with any particular hematological malignancy and provides further insight into the range of cytogenetic abnormalities in MDS.
- [VIRTUAL] NKp30-CAR reprogrammed, TCR-negative T lymphocytes induce potent antitumor reactivity against acute myeloid leukemia expressing B7H6 and in melanoma (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2196;
NKp30 CAR TCRKO T cells successfully elicit immunity both to AML and solid tumors such as melanoma. As to this end, B7H6 is tumor-specific, this antigen might be a promising target for ACT to AML.
- [VIRTUAL] NKp30-CAR reprogrammed, TCR-negative T lymphocytes induce potent antitumor reactivity against acute myeloid leukemia expressing B7H6 and in melanoma (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1482;
NKp30 CAR TCRKO T cells successfully elicit immunity both to AML and solid tumors such as melanoma. As to this end, B7H6 is tumor-specific, this antigen might be a promising target for ACT to AML.
- [VIRTUAL] NKp30-CAR reprogrammed, TCR-negative T lymphocytes induce potent antitumor reactivity against acute myeloid leukemia expressing B7H6 and in melanoma (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_688;
NKp30 CAR TCRKO T cells successfully elicit immunity both to AML and solid tumors such as melanoma. As to this end, B7H6 is tumor-specific, this antigen might be a promising target for ACT to AML.
- [VIRTUAL] NKp30-CAR reprogrammed, TCR-negative T lymphocytes induce potent antitumor reactivity against acute myeloid leukemia expressing B7H6 and in melanoma (Nairobi) - Sep 3, 2020 - Abstract #DGHO2020DGHO_289;
NKp30 CAR TCRKO T cells successfully elicit immunity both to AML and solid tumors such as melanoma. As to this end, B7H6 is tumor-specific, this antigen might be a promising target for ACT to AML.
- [VIRTUAL] Integration of new substances into the first-line therapy of the fit patient (Osaka) - Sep 3, 2020 - Abstract #DGHO2020DGHO_275;
If alloSCT is not an option, midostaurin, GO and CPX-351 are approved as part of consolidation chemotherapy in the respective AML subgroups. Two scenarios may shape the future of curative treatment: First, the combination of an intensive chemotherapy backbone with novel agents such as second-generation TKIs, IDH or BCL2 inhibitors, or alternatively, the replacement of intensive chemotherapy by novel combinations such as hypomethylating agents plus BCL2 inhibitors plus/minus targeted drugs.
- | Money would be on t(8;21). If so maybe CD19+, weak CD33 and possible CD56+. (Twitter) - Sep 3, 2020
- Mozobil (plerixafor) / Sanofi
[VIRTUAL] CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS (ePoster Area) - Sep 2, 2020 - Abstract #EBMT2020EBMT_6347;
In accordance with the literature data, the three different mobilization regimens did not provide adequate MLP and BLP in the peripheral blood. Early engraftment kinetics were not affected by given CD34+ cell subsets.
- | Journal: A CD33 antigen targeted AAV6 vector expressing an inducible caspase-9 suicide gene is therapeutic in a xenotransplantation model of acute myeloid leukemia. (Pubmed Central) - Sep 2, 2020
We observed a significant anti-leukemic effect with AAV6-CD33 vectors, with a markedly higher survival (100% for AAV6-CD33 vectors vs. 15% for mock-treated) and higher number of TUNEL positive apoptotic cells after systemic vector delivery. Taken together, our work demonstrates the efficacy and translational potential of CD33-targeted AAV6 vectors for cytotoxic gene therapy in AML.
- Imbruvica (ibrutinib) / AbbVie, J&J
[VIRTUAL] Targeting Myeloid-derived Suppressor Cells with Ibrutinib Enhances Therapeutic Response to anti-pd-l1 Immune Checkpoint Blockade (Virtual Meeting Room 4) - Sep 1, 2020 - Abstract #SSO2020SSO_79;
These results show that BTK is important in MDSC biology and its downstream effector functions. Targeted inhibition of MDSC is a novel strategy to enhance the immune therapy of advanced melanoma.
- ||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, P3 data, Journal: Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. (Pubmed Central) - Aug 30, 2020
The trial did not meet its early primary end point of EFS, mainly as a result of a higher early death rate in the GO arm. However, in patients achieving CR/CRi after induction therapy, significantly fewer relapses occurred in the GO compared with the standard arm.
- Simulect (basiliximab) / Novartis
[VIRTUAL] Myeloid derived suppressor cells (MDSC) in kidney recipients: Identification of CD25+eMDSC, and augmentation of monocytic-MDSC early after transplantation in patients later developing cancer (Channel 7) - Aug 29, 2020 - Abstract #TTS2020TTS_388;
M-MDSC may favor an immunosuppressive environment that promotes the tumoral development. A CD25+eMDSC subset has been identified which is under study.
- || Clinical, Journal: Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. (Pubmed Central) - Aug 27, 2020
The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
- | Journal: CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. (Pubmed Central) - Aug 23, 2020
GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series. No abstract available
- || bortezomib / Generic mfg.
Clinical, Journal: Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib. (Pubmed Central) - Aug 23, 2020
Moreover, the present results demonstrated that at the relapse of disease, the percentage of CD33 increased (median 48.7%) and MPC-1 decreased (median 14.1%), respectively, therefore, both of these antigens may be associated with the refractory disease status. The present study showed that the expression of CD33 and MPC-1 in neoplastic plasma cells from patients with MM was associated with patient prognosis independent of other prognostic factors.
- || cytarabine / Generic mfg., Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, Journal: Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience. (Pubmed Central) - Aug 18, 2020
FLA-GO is a good salvage regimen for pediatric refractory AML, with significant but acceptable toxicity. HSCT is mandatory to achieve sustained CR in these patients.
- | thanks for sharing! Indeed quite a bunch of CARTs in development in China - CD19, CD33, CD123... (Twitter) - Aug 17, 2020
- [VIRTUAL] Synthetic agonistic receptor-activating BiTEs - a modular platform for the efficient targeting of acute myeloid leukemia () - Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_54;
With a lack of truly specific AML antigens, it is invaluable that this approach possesses an intrinsic safety switch via its BiTE facet. Moreover, we are able to circumvent pan-T cell activation due to the specific targeting and activation of SAR T cells.
- | Preclinical, Journal, Myeloid-derived suppressor cells: Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells. (Pubmed Central) - Aug 14, 2020
MDSC are a heterogenous group of cells, and their quantitation in WB can be affected by a number of pre-analytical variables. Consideration of these factors, and measurement using a material type that has not been manipulated, such as whole blood, is likely to yield the most accurate results.
- | Journal: Comparative phenotypic characterization of human colostrum and breast milk-derived stem cells. (Pubmed Central) - Aug 11, 2020
Our findings form flow cytometry and cell culture suggest that the lactation stage could be one of the factors influencing the stem cell population and, consequently, the cultivation of breastmilk cells. The present study indicates that colostrum is a tremendous source of stem cells that could be applied in cell-based research.
- [VIRTUAL] Recognition of Plasmacytoid Dendritic Cells in CSF Sample from Patient with History of B-Lymphoblastic Leukemia to Avoid Potential Overdiagnosis and Overtreatment () - Aug 7, 2020 - Abstract #ISLH2020ISLH_131;
The morphology of PDCs poses challenges when examining CSF in patients with hematologic malignancies. PDC morphology has been well-described in traditional H&E staining, but morphologic descriptions in cytopathology are few. In CSF, PDCs display cytological features mimicking blasts, making differentiation difficult. In this patient, flow cytometry was helpful in identifying PDCs. Awareness of the presence of PDCs may help to avoid potential misclassification of PDCs as blasts and to avoid overtreatment.
- [VIRTUAL] Pediatric blastic plasmacytoid dendritic cell neoplasm: case report of a rare hematologic malignancy () - Aug 7, 2020 - Abstract #ISLH2020ISLH_75;
BPDCN is a rare hematologic malignancy, especially in pediatric settings, and is characterized by an aggressive course and poor prognosis. Despite the myeloid origin of BPDCN, ALL-like treatments have better outcomes, so making a correct distinction with AML is of great importance.
- | Journal, IO biomarker: Single-agent and combination biologics in acute myeloid leukemia. (Pubmed Central) - Aug 5, 2020
With new targeted agents available, comprehensive genomic characterization of AML at diagnosis and relapse is increasingly necessary to select optimal treatment. Herein, we review the new single-agent and combination biologics (omitting FLT3 inhibitors, which are discussed separately) and provide recommendations on how to best use and manage patients on these regimens in clinical practice.
- | Journal: Vor Nets $110m to Make Anti-CD33 Drugs Safer. (Pubmed Central) - Aug 5, 2020
Vor Biopharma secured $110 million in July to move its CD33-inactivated cell therapy into clinical testing. The company's hope is that patients with high-risk acute myeloid leukemia who receive transplants of the gene-edited stem cells will then better tolerate therapies designed to destroy cells expressing CD33, an antigen found in abundance on leukemic blasts.
- [VIRTUAL] Discovery of novel tumor-associated exonic incertions of polymorphic retroelements in human genome (Interactive e-Poster Area) - Aug 4, 2020 - Abstract #ESHG2020ESHG_1229;
Frequency of bi-allelic PREI (AluYa5) in PRAMEF4 gene exon was significantly higher in healthy female cohort compared to healthy males (p-value=0.05, two-tailed Fisher's exact test) and in T-lineage leukemia male cohort compared to healthy male donors (p-value=0.01). Leukemia samples with bi-allelic PREI in PRAMEF4 had specific (p-value=0.008) immunophenotype: CD33-CD13-CD34-CD117-CD56-CD1a+CD3+CD4+CD8+CD10+ inherent to more mature lymphoblasts.
- [VIRTUAL] High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements in B-lineage acute lymphoblastic leukemia (Interactive e-Poster Area) - Aug 4, 2020 - Abstract #ESHG2020ESHG_916;
The innovative study provides pathbreaking analyses of TRA occurrence in B-ALL at the DNA level and suggests that particular TRA rearrangements may be of clinical relevance in childhood B-ALL by adding a significant marker to MRD detection panel based on TCR/BCR rearrangements analysis. The study is supported by PFBR grants 20-015-00462, 18-29-09132.
- antolimab (AK002) / Allakos
[VIRTUAL] Eosinophil siglecs: biology and therapeutic advances (p.541) - Aug 2, 2020 - Abstract #WAC2020WAC_152;
Finally, a biotechnology company called Allakos, Inc. has created a humanized non-fucosylated IgG1 monoclonal antibody named antolimab (formerly called AK002) that is being tested in clinical trials for the treatment of various diseases involving eosinophils and/or mast cells including eosinophilic gastrointestinal diseases, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
- || vadastuximab talirine (SGN-CD33A) / Seattle Genetics
Clinical, Journal: CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. (Pubmed Central) - Aug 2, 2020
We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
- [VIRTUAL] CD33, MEF2C, and SORL1 are Associated with Variability in Macroscale Functional Brain Architecture in AD () - Aug 2, 2020 - Abstract #AAIC2020AAIC_2625;
These findings establish the GFSS as a useful endophenotype for genetic analyses, particularly as an avenue toward a mechanistic understanding of how heritable factors may influence inter-individual variability and syndromic diversity in AD. Further investigation in larger and independent cohorts is warranted.
- [VIRTUAL] Identification of multi-issue protein quantitative trait loci (pQTLs) for Alzheimer Disease () - Aug 2, 2020 - Abstract #AAIC2020AAIC_1896;
Taken together, these findings prioritized the proteins for the functional validation study. Thus, the findings helped identify potential biomarkers for AD or other neurological traits.
- [VIRTUAL] Genetic associations in Alzheimers Disease: A systematic review and meta-analysis () - Aug 2, 2020 - Abstract #AAIC2020AAIC_1800;
Our findings acknowledged significant associations of three SNPs: rs3865444, rs7561528 and rs1801133 with Alzheimers risk. This evidence has to be replicated further to substantiate the role of aforesaid SNPs in AD.
- [VIRTUAL] The late-onset Alzheimer's disease genetic risk factor CD2AP impacts synapses via actin dynamics (Virtual Room Name: Session Chatroom) - Aug 2, 2020 - Abstract #AAIC2020AAIC_909;
A LOAD mutant CD2AP may interfere with its function by dysregulating actin dynamics at spines. Overall CD2AP variants may contribute to LOAD development by directly interfering with synapses.
- |||||| Actimab-A (lintuzumab-Ac225) / Actinium
Clinical: @ActiniumPharma The most aggressive type of leukemia is AML & Actimab-A plus CLAG-M combination trial has shown 86% remission rate with 71% MRD negative rate in CD33 positive patients. @JNJCares @Roche @abbvie (Twitter) - Aug 1, 2020
- | Journal, Myeloid-derived suppressor cells: Extravasated platelet aggregation contributes to tumor progression via the accumulation of myeloid-derived suppressor cells in gastric cancer with peritoneal metastasis. (Pubmed Central) - Jul 30, 2020
These results indicated that EPA affects immunosuppression by recruiting MDSCs in the tumor microenvironment via the secretion of soluble factors, resulting in tumor progression. EPA may be a novel therapeutic target for gastric cancer with peritoneal metastasis.
- | Journal: Decreased erythrocyte binding of Siglec-9 increases neutrophil activation in sickle cell disease. (Pubmed Central) - Jul 29, 2020
Stimulated neutrophils incubated with AA erythrocytes showed minimal NET formation while with SS erythrocytes NETs increased. SS erythrocytes are deficient in binding to neutrophil Siglec-9 which may contribute to the increased oxidative stress in SCD.
- | Biomarker, Journal: Effects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders. (Pubmed Central) - Jul 25, 2020
These results suggested that the two CD33 common variants (rs3826656 and rs3865444) influenced volumes and atrophy rates of AD-related brain regions in non-demented elders. Subgroup analyses showed the effects mainly existed in the Aβ-positive group instead of the Aβ-negative group, and the effects began in the prodromal AD stage.
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Clinical, Journal: Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial. (Pubmed Central) - Jul 25, 2020
Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR 0.43, 95%CI[0.28-0.65]) which correlated to higher CD33 expression levels. These results suggest that molecular aberrations could be critical for future differentially tailored treatments based on integrated genetic profiles able to predict the benefit of GO on outcome.
- ||||| Residual disease: Please join me in welcoming Roland Walter MD PhD to twitter @RolandBWalter. Dr. Walter is a world expert in Acute Myeloid Leukemia from the @fredhutch particularly known for his work on CD33 targeted therapy, allo-transplant and measurable residual disease (MRD). (Twitter) - Jul 24, 2020
- | Journal: The Impact of Ag Nanoparticles and CdTe Quantum Dots on Expression and Function of Receptors Involved in Amyloid-β Uptake by BV-2 Microglial Cells. (Pubmed Central) - Jul 24, 2020
To summarize, we showed that AgNP uptake competes with Aβ uptake by microglial cells and consequently can impair the removal of the aggregates. In turn, CdTeQD treatment led to the accumulation of proinflammatory Cd36 protein on the cell surface.
- || Review, Journal: The Time Has Come for Targeted Therapies for AML: Lights and Shadows. (Pubmed Central) - Jul 24, 2020
These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
- | Journal: Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? (Pubmed Central) - Jul 21, 2020
Additionally, the IDH1 inhibitor ivosidenib has received FDA approval in July 2018...Herein, we review the mechanisms of actions and preclinical data, highlight pivotal clinical trial data, and discuss future directions and challenges for further development of these 5 novel therapeutics. Finally, we briefly overview some of the highly promising agents that are currently in advanced stages of clinical development.
- || Clinical, Review, Journal: Evaluation of CD33 as a genetic risk factor for Alzheimer's disease. (Pubmed Central) - Jul 21, 2020
However, this interpretation may need to be reconsidered given current findings that a genetic deletion which abrogates CD33 is not associated with Alzheimer's disease risk. Therefore, integrating currently available findings leads us to propose a model wherein the CD33 isoform lacking the ligand-binding domain represents a gain of function variant that reduces Alzheimer's disease risk.
- | Hi Pembe - pretty standard B-ALL phenotype with CD19, CD10, CD34, CD22, and TdT, and no MPO or aberrant myeloid expression (CD33, CD13). (Twitter) - Jul 19, 2020
- | Rydapt (midostaurin) / Novartis
Journal: Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. (Pubmed Central) - Jul 18, 2020
This information is of relevance for clinicians exploring T-cell mediated immunotherapy in early clinical trials. Given the profound inhibition of T-cell functionality and anti-tumour activity, we recommend specific FLT3 TKIs for further clinical testing of combinatory approaches with T-cell based immunotherapy.
- ||| Venclexta (venetoclax) / Roche, AbbVie, Actimab-A (lintuzumab-Ac225) / Actinium
$ATNM perfect fit to be acquired by @roche @genentech conducting 2 trials 1) ph 1/2 Actimab-A (CD33) and Venetoclax in Relapsed/Refractory AML 2) ph 1 Actimab-A (CD33) and Venetoclax with HMA in Relapsed/Refractory AML (Twitter) - Jul 17, 2020
- | Journal: Cellular Subsets of Maternal Microchimerism in Umbilical Cord Blood. (Pubmed Central) - Jul 16, 2020
Overall, four of the five (80%) positive samples were from Cesarean sections and one was from a vaginal delivery. The conclusion from this study is that maternal microchimerism in umbilical cord blood is not a common phenomenon but includes both lymphoid and hematopoietic progenitor lineages.